These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

590 related items for PubMed ID: 10826401

  • 41. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A, Calvo C, García-Puig J, Gil-Extremera B, Aguilera MT, de la Sierra A, Martín-Hidalgo A, Marín R, MAPAVEL Investigators (Monitorizacíon Ambulatoria Presión Arterial APROVEL).
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [Abstract] [Full Text] [Related]

  • 42. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY, Hong BK, Chung WJ, Lee BK, Lee SH, Jeon DW, Ahn YK, Kim D, Park CK, Kim SH, Jung HO, Kim BO, Choi D.
    Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
    [Abstract] [Full Text] [Related]

  • 43. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan.
    Andersson OK, Neldam S.
    Blood Press; 1998 Jan; 7(1):53-9. PubMed ID: 9551878
    [Abstract] [Full Text] [Related]

  • 44. Management of hypertension with fixed dose combinations of candesartan cilexetil and hydrochlorothiazide: patient perspectives and clinical utility.
    Mengden T, Uen S, Bramlage P.
    Vasc Health Risk Manag; 2009 Jan; 5():1043-58. PubMed ID: 20057897
    [Abstract] [Full Text] [Related]

  • 45. Comparison of the combination of enalapril and a very low dose of hydrochlorothiazide with atenolol in patients with mild-to-moderate hypertension. Scandinavian Study Group.
    Os I, Hotnes T, Dollerup J, Mogensen CE.
    Am J Hypertens; 1997 Aug; 10(8):899-904. PubMed ID: 9270085
    [Abstract] [Full Text] [Related]

  • 46. Regional hemodynamic effects of candesartan cilexetil (TCV-116), an angiotensin II AT1-receptor antagonist, in conscious spontaneously hypertensive rats.
    Kanagawa R, Wada T, Sanada T, Ojima M, Inada Y.
    Jpn J Pharmacol; 1997 Mar; 73(3):185-90. PubMed ID: 9127812
    [Abstract] [Full Text] [Related]

  • 47. A Combination of Candesartan Cilexetil/hydrochlorothiazide (HCTZ), 8/12.5 mg, has a Similar Antihypertensive Efficacy and is Better Tolerated than Lisinopril/HCTZ, 10/12.5 mg.
    T McINNES G, Istad H, Keinänen-Kiukaanniemi S, VAN Mierlo HFCM.
    Blood Press; 2000 Mar; 9(sup1):61. PubMed ID: 28425809
    [Abstract] [Full Text] [Related]

  • 48. Switch from ABCD pretreatment to A-II-A treatment: a multinational, open, centrally randomized, prospective parallel group comparison.
    Asmar R, Porcellati C, Dusing R.
    Drugs Exp Clin Res; 2004 Mar; 30(4):153-61. PubMed ID: 15553661
    [Abstract] [Full Text] [Related]

  • 49. Candesartan cilexetil/hydrochlorothiazide treatment in high-risk patients with type 2 diabetes mellitus and microalbuminuria: the CHILI T2D study.
    Ketelhut R, Bramlage P.
    Clin Drug Investig; 2010 Mar; 30(5):301-11. PubMed ID: 20384386
    [Abstract] [Full Text] [Related]

  • 50. Effects of candesartan cilexetil and enalapril on structural alterations and endothelial function in small resistance arteries of spontaneously hypertensive rats.
    Rizzoni D, Porteri E, Bettoni G, Piccoli A, Castellano M, Muiesan ML, Pasini G, Guelfi D, Rosei EA.
    J Cardiovasc Pharmacol; 1998 Nov; 32(5):798-806. PubMed ID: 9821855
    [Abstract] [Full Text] [Related]

  • 51. Efficacy, tolerability, and quality of life of losartan, alone or with hydrochlorothiazide, versus nifedipine GITS in patients with essential hypertension.
    Weir MR, Elkins M, Liss C, Vrecenak AJ, Barr E, Edelman JM.
    Clin Ther; 1996 Nov; 18(3):411-28. PubMed ID: 8829017
    [Abstract] [Full Text] [Related]

  • 52. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Rakugi H, Ogihara T, Miyata Y, Sasai K, Totsuka N.
    Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
    [Abstract] [Full Text] [Related]

  • 53. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension.
    Agrawal R, Marx A, Haller H.
    J Hypertens; 2006 Jan; 24(1):185-92. PubMed ID: 16331117
    [Abstract] [Full Text] [Related]

  • 54. A Randomized, Double-blind, Candesartan-controlled, Parallel Group Comparison Clinical Trial to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Patients with Mild to Moderate Essential Hypertension.
    Lee JH, Yang DH, Hwang JY, Hur SH, Cha TJ, Kim KS, Kim MH, Chun KJ, Cha GS, Hong GR, Lee SG, Kim DS, Kim DI, Chae SC.
    Clin Ther; 2016 Jun; 38(6):1485-1497. PubMed ID: 27161546
    [Abstract] [Full Text] [Related]

  • 55. Improvement in exercise tolerance and symptoms of congestive heart failure during treatment with candesartan cilexetil. Symptom, Tolerability, Response to Exercise Trial of Candesartan Cilexetil in Heart Failure (STRETCH) Investigators.
    Riegger GA, Bouzo H, Petr P, Münz J, Spacek R, Pethig H, von Behren V, George M, Arens H.
    Circulation; 1999 Nov 30; 100(22):2224-30. PubMed ID: 10577995
    [Abstract] [Full Text] [Related]

  • 56. A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure. Candesartan cilexetil in Hypertension Ambulatory Measurement of Blood Pressure (CHAMP) Study Investigators.
    Asmar R, Lacourcière Y.
    J Hypertens; 2000 Nov 30; 18(11):1683-90. PubMed ID: 11081784
    [Abstract] [Full Text] [Related]

  • 57. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group.
    Howe P, Phillips P, Saini R, Kassler-Taub K.
    Clin Exp Hypertens; 1999 Nov 30; 21(8):1373-96. PubMed ID: 10574419
    [Abstract] [Full Text] [Related]

  • 58. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep 30; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 59. Effects of candesartan cilexetil on health-related quality of life in black patients with systemic hypertension in the ABC Trial.
    Zyczynski TM, Leidy NK, Kong BW, Helaszek CT, Michelson EL, Association of Black Cardiologists (ABC) Candesartan Study Group.
    Heart Dis; 2000 Sep 30; 2(6):400-6. PubMed ID: 11728290
    [Abstract] [Full Text] [Related]

  • 60. Increased efficacy and tolerability with losartan plus hydrochlorothiazide in patients with uncontrolled hypertension and therapy-related symptoms receiving two monotherapies.
    Naidoo DP, Sareli P, Marin F, Aroca-Martinez G, Maritz FJ, Jardim PC, Guerrero AA, Thompson CA, Bero T, Drazka J, Kosmalova V, Dumortier T, Smith RD.
    Adv Ther; 1999 Sep 30; 16(5):187-99. PubMed ID: 10915394
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.